OREX - Sector: Healthcare---Industry: Biotechnology & Drugs

[setravis]

8 Promising Biotech Buyout Targets if Their Products Can Deliver...

The following are a few biotechs with promising products in their pipelines that have made the big boys sit up and take notice. Without further ado, the 8 promising biotechs priced for a buyout if their products can deliver:

Orexigen Therapeutics Inc. (OREX): Like Vivus, Orexigen has a weight-loss pill, Contrave, awaiting FDA approval. The FDA rejected Contrave in February, citing concerns about its cardiovascular side effects. Orexigen received good news from studies on Monday; data from a late-stage study showed that patients taking Contrave maintained normal blood pressure patterns around the clock during a full year of treatment. The results indicate that the drug does not have cardiovascular effects, and should help the drug's status in the eyes of the FDA. While Contrave seems closer to approval than Arena's Lorcaserin and Vivus's Qnexa, we're still skeptical about the safety of weight-loss drugs in general, and don't place great expectation on any of the drugs reaching the market. Some analysts predict that the next weight-loss drug to make it to market could be a billion dollar seller. While the reward sounds great, the risk involved with all three drugs make us doubt that they will get to that point.
Shares currently trade at $2.90

Technicals
Last Price Quote is:
-0.93%below 13-day EMA
-18.48%below 50-day EMA
RS Rating: 2